Rate My Professor Masakazu Kamata

Kamata has authored over 50 peer-reviewed manuscripts, with 28 focused on HIV cure research. Key publications include "Site-oriented conjugation of poly(2-methacryloyloxyethyl phosphorylcholine) for enhanced brain delivery of antibody" (Frontiers in Cell and Developmental Biology, 2023), demonstrating fivefold improved brain penetration of modified trastuzumab without toxicity; "JNK knockdown enhances CAR-T cell cytotoxicity through elevated NFATc1-dependent transcription in preclinical ovarian cancer models" (2025); and "Efficient derivation of chimeric-antigen receptor-modified T cells from hematopoietic stem/progenitor cells" (Frontiers in Immunology, 2022). His work has garnered substantial funding exceeding $3 million over five years from the National Institutes of Health (R01, R21, P30 supplements), Cancer Research Institute, and The Brain Charity (UK). Recent honors include a 2025 NIH 1R01 award for novel nanotherapy, an O'Neal Comprehensive Cancer Center Pre-R01 grant for durable anti-ovarian cancer control via combinational T-cell engagement, and recognition as Most Prolific Inventor by UAB's Bill L. Harbert Institute for Innovation and Entrepreneurship. Kamata has mentored trainees at RIKEN in Japan, UCLA, and UAB, many achieving awards for presentations.